Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:XTLB

XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis

About XTL Biopharmaceuticals Stock (NASDAQ:XTLB)

Advanced Chart

Key Stats

Today's Range
$1.13
$1.13
50-Day Range
$3.43
$5.20
52-Week Range
$0.86
$3.05
Volume
N/A
Average Volume
27,742 shs
Market Capitalization
$7.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive XTLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XTLB Stock News Headlines

Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
XTL Biopharmaceuticals Ltd. (XTLB) - Yahoo Finance
XTL Biopharmaceuticals names Noam Band as CEO
XTL Biopharmaceuticals Appoints Noam Band as CEO
See More Headlines

XTLB Stock Analysis - Frequently Asked Questions

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced its quarterly earnings results on Monday, December, 30th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter.

XTL Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017.The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Regulus Therapeutics (RGLS), Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP).

Company Calendar

Last Earnings
12/30/2024
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED-DRUGS
Sub-Industry
N/A
Current Symbol
NASDAQ:XTLB
CIK
1023549
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.61
Quick Ratio
0.61

Sales & Book Value

Annual Sales
$450 thousand
Price / Sales
16.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.00 per share
Price / Book
1.37

Miscellaneous

Outstanding Shares
5,450,000
Free Float
3,869,000
Market Cap
$7.47 million
Optionable
Not Optionable
Beta
1.09
10 Stocks Set to Soar in Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:XTLB) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners